Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic Logo Current.jpg
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
October 05, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic to Present at Industry and Investor Events in October
September 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October
VIR_logo_large.jpg
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023 08:00 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
Lucira_COVID-19_&_Flu_Home_Test_packaging_and_device
Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process
March 28, 2023 08:05 ET | Lucira Health Inc.
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access...
4 Pack
eMed launches first-of-its-kind eMed® Urgent Care Telehealth Kit™, enabling access to same-day clinical evaluations and prescription medications for four common illnesses
March 03, 2023 11:09 ET | eMed
MIAMI, March 03, 2023 (GLOBE NEWSWIRE) -- eMed, the leader in at-home, test-to-treat telehealth kits, today announced the first-of-its-kind eMed® Urgent Care Telehealth Kit™. Powered by eMed's...
Image w slogan.png
New Technology Can Now Test for Airborne COVID and Several Strains of the Common Flu
March 01, 2023 23:35 ET | AirAnswers Inc
NORTH CHICAGO, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- AirAnswers, the leader in air sampling and testing technology, is expanding their test offering to include a panel of airborne viruses...
The blue and green boxed packaging of the FDA EUA authorized Lucira COVID-19 & Flu Home Test pictured next to the test device itself
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
February 27, 2023 08:00 ET | Lucira Health Inc.
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access...
XWELL_Black_CMYK.jpg
Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
January 17, 2023 08:00 ET | XWELL, Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease...
VIR_logo_large.jpg
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
December 21, 2022 08:00 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...